GlassScriptPhysician profile
Rodolfo Molina
NPI 1083619605
$9,262.20
in general payments reported to CMS, 2019-2025
35 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,293 · 2020: $1,833 · 2021: $2,210 · 2022: $635 · 2023: $1,334 · 2024: $550 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,291.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,112.97 | 2021-2025 | |
| Allergan, INC. | $869.43 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $854.26 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $853.08 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $816.47 | 2019-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $705.46 | 2020-2024 | Caplyta |
| Lundbeck LLC | $522.64 | 2019-2024 | Rexulti |
| Alkermes, INC. | $459.27 | 2020-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $425.22 | 2019-2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $371.44 | 2019-2021 | |
| Corium, LLC | $336.43 | 2023-2025 | Azstarys |
| Janssen Biotech, INC. | $260.28 | 2025 | Simponi Aria, Tremfya |
| Tris Pharma INC | $245.09 | 2023-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Bausch Health US, LLC | $240.88 | 2019-2024 | Aplenzin |
| Jazz Pharmaceuticals INC. | $214.83 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $150.41 | 2020-2023 | |
| Neos Therapeutics, LP | $121.21 | 2021-2024 | Adzenys Xr-Odt |
| Eisai INC. | $85.60 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $77.92 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $72.25 | 2025 | Saphnelo |
| Avanir Pharmaceuticals, INC. | $67.26 | 2019 | |
| Vanda Pharmaceuticals INC. | $54.37 | 2019 | |
| Sanofi-Aventis U.S. LLC | $45.74 | 2019 | |
| Adlon Therapeutics L.P. | $41.53 | 2019-2020 | |
| Sandoz INC. | $35.00 | 2020 | |
| Ironshore Pharmaceuticals INC. | $34.88 | 2020 | |
| Neuronetics, INC. | $34.22 | 2019 | |
| Indivior INC. | $24.88 | 2019 | |
| Idorsia Pharmaceuticals US INC | $24.16 | 2024 | Quviviq |
| Biogen, INC. | $22.72 | 2024 | Vumerity |
| Arbor Pharmaceuticals, INC. | $18.92 | 2019 | |
| Avion Pharmaceuticals | $17.76 | 2024 | Methylphenidate Hydrochloride |
| Abbott Laboratories | $16.85 | 2019 | |
| Noven Therapeutics, LLC | $15.94 | 2020 | |
| Shire North American Group INC | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodolfo Molina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.